Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Afatinib enhances the efficacy of conventional chemotherapeutic agents by eradicating cancer stem-like cells.

Wang XK, He JH, Xu JH, Ye S, Wang F, Zhang H, Huang ZC, To KK, Fu LW.

Cancer Res. 2014 Aug 15;74(16):4431-45. doi: 10.1158/0008-5472.CAN-13-3553. Epub 2014 Jun 27.

2.

Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.

Wang XK, To KK, Huang LY, Xu JH, Yang K, Wang F, Huang ZC, Ye S, Fu LW.

Oncotarget. 2014 Dec 15;5(23):11971-85.

3.

Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.

Wang F, Mi YJ, Chen XG, Wu XP, Liu Z, Chen SP, Liang YJ, Cheng C, To KK, Fu LW.

Mol Med. 2012 Jul 18;18:887-98. doi: 10.2119/molmed.2011.00444.

4.

Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.

Hu J, Zhang X, Wang F, Wang X, Yang K, Xu M, To KK, Li Q, Fu L.

Oncotarget. 2015 Dec 29;6(42):44643-59. doi: 10.18632/oncotarget.5989.

5.

Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma.

Hou H, Sun H, Lu P, Ge C, Zhang L, Li H, Zhao F, Tian H, Zhang L, Chen T, Yao M, Li J.

Mol Cancer Ther. 2013 Dec;12(12):2874-84. doi: 10.1158/1535-7163.MCT-13-0201. Epub 2013 Oct 15.

6.

Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202.

Cheng C, Liu ZG, Zhang H, Xie JD, Chen XG, Zhao XQ, Wang F, Liang YJ, Chen LK, Singh S, Chen JJ, Talele TT, Chen ZS, Zhong FT, Fu LW.

Mol Pharm. 2012 Jul 2;9(7):1971-82. doi: 10.1021/mp2006714. Epub 2012 Jun 13.

PMID:
22632055
7.

Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.

Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S.

Cancer Res. 2005 Feb 15;65(4):1541-6.

8.

Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via β-catenin/ABCG2 signaling.

Wang N, Wang Z, Peng C, You J, Shen J, Han S, Chen J.

Carcinogenesis. 2014 Nov;35(11):2544-54. doi: 10.1093/carcin/bgu187. Epub 2014 Sep 6.

PMID:
25194164
9.

Topotecan-induced ABCG2 expression in MCF-7 cells is associated with decreased CD24 and EpCAM expression and a loss of tumorigenicity.

Huber S, Wege AK, Bernhardt G, Buschauer A, Brockhoff G.

Cytometry A. 2015 Aug;87(8):707-16. doi: 10.1002/cyto.a.22675. Epub 2015 Apr 17.

10.

Mithramycin represses basal and cigarette smoke-induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cells.

Zhang M, Mathur A, Zhang Y, Xi S, Atay S, Hong JA, Datrice N, Upham T, Kemp CD, Ripley RT, Wiegand G, Avital I, Fetsch P, Mani H, Zlott D, Robey R, Bates SE, Li X, Rao M, Schrump DS.

Cancer Res. 2012 Aug 15;72(16):4178-92. doi: 10.1158/0008-5472.CAN-11-3983. Epub 2012 Jul 2.

11.

Nilotinib enhances the efficacy of conventional chemotherapeutic drugs in CD34⁺CD38⁻ stem cells and ABC transporter overexpressing leukemia cells.

Wang F, Wang XK, Shi CJ, Zhang H, Hu YP, Chen YF, Fu LW.

Molecules. 2014 Mar 19;19(3):3356-75. doi: 10.3390/molecules19033356.

12.

Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2.

Zhao XQ, Dai CL, Ohnuma S, Liang YJ, Deng W, Chen JJ, Zeng MS, Ambudkar SV, Chen ZS, Fu LW.

Eur J Pharm Sci. 2013 Jun 14;49(3):441-50. doi: 10.1016/j.ejps.2013.04.015. Epub 2013 Apr 22.

PMID:
23619284
13.

Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.

Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW.

Cancer Lett. 2009 Jun 28;279(1):74-83. doi: 10.1016/j.canlet.2009.01.027. Epub 2009 Feb 18.

PMID:
19232821
14.

Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.

Katayama R, Koike S, Sato S, Sugimoto Y, Tsuruo T, Fujita N.

Cancer Sci. 2009 Nov;100(11):2060-8. doi: 10.1111/j.1349-7006.2009.01288.x. Epub 2009 Jul 17.

15.

ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan.

Shishido Y, Ueno S, Yamazaki R, Nagaoka M, Matsuzaki T.

Anticancer Res. 2013 Apr;33(4):1379-86.

PMID:
23564776
16.

Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells.

Martín V, Sanchez-Sanchez AM, Herrera F, Gomez-Manzano C, Fueyo J, Alvarez-Vega MA, Antolín I, Rodriguez C.

Br J Cancer. 2013 May 28;108(10):2005-12. doi: 10.1038/bjc.2013.188. Epub 2013 Apr 30.

17.

Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.

Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins JJ 3rd, Gilbertson R, Germain GS, Harwood FC, Houghton PJ.

Cancer Res. 2004 Oct 15;64(20):7491-9.

18.

Emodin as an effective agent in targeting cancer stem-like side population cells of gallbladder carcinoma.

Li XX, Dong Y, Wang W, Wang HL, Chen YY, Shi GY, Yi J, Wang J.

Stem Cells Dev. 2013 Feb 15;22(4):554-66. doi: 10.1089/scd.2011.0709. Epub 2012 Nov 7.

19.

ABCG2 expression, function, and promoter methylation in human multiple myeloma.

Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS, Sullivan DM.

Blood. 2006 Dec 1;108(12):3881-9. Epub 2006 Aug 17.

20.

Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic.

Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG.

Cancer Res. 2005 Jul 15;65(14):6207-19.

Supplemental Content

Support Center